Yang Biao, He Jian-Ping, Yuan Min-Lan, Li Wei, Jiao He, You Xin, Liu Xing-Rong, Zhao Jian, Li Chun-Lin, Fu Xiao-Bo, Liao Zheng-Yin, Yi Cheng
Department of Abdominal Oncology, Cancer Center and State Key Laboratory of Biotherapy Department of Psychiatry Department of Radiology, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Medicine (Baltimore). 2017 Sep;96(37):e8018. doi: 10.1097/MD.0000000000008018.
The aim of this study was to determine the effectiveness of intratumoral injection of chemotherapeutics in improving the quality of life and survival of patients with pancreatic carcinoma.
We present a case series of 5 patients with unresectable pancreatic adenocarcinoma.
Patients diagnosed with unresectable poorly differentiated pancreatic ductal adenocarcinoma by intraoperative frozen biopsyor percutaneous biopsy.
Five patients with unresectable pancreatic adenocarcinoma received a computed tomography-guided percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue.
Mean overall survival was 16.2 ± 3.7 months. Local control rates were 100% and 80% at postoperative 3 and 6 months, respectively. Mean Visual Analogue Scale pain score decreased from 7.2 ± .84 preoperatively to 2 ± 1.22 at postoperative 4 weeks. There were no complications associated with the procedure.
Percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue for advanced pancreatic may be safe and effective.
本研究的目的是确定瘤内注射化疗药物对改善胰腺癌患者生活质量和生存率的有效性。
我们展示了一组5例不可切除胰腺癌患者的病例系列。
通过术中冰冻活检或经皮活检诊断为不可切除的低分化胰腺导管腺癌患者。
5例不可切除胰腺癌患者接受了计算机断层扫描引导下经皮瘤内注射吉西他滨加顺铂与纤维蛋白胶混合液。
平均总生存期为16.2±3.7个月。术后3个月和6个月的局部控制率分别为100%和80%。平均视觉模拟评分疼痛评分从术前的7.2±0.84降至术后4周的2±1.22。该操作无相关并发症。
经皮瘤内注射吉西他滨加顺铂与纤维蛋白胶混合液治疗晚期胰腺癌可能是安全有效的。
